Immunization Newsbriefs (c) Copyright Information Inc., Bethesda, MD. Brought to you by the National Network for Immunization Information (NNii). Visit NNii's new website at http://www.immunizationinfo.org.
------------------------------------------------------------
June 28, 2002
U.S. IMMUNIZATION NEWS
"In Vitro Studies of Core Peptide-Bearing Immunopotentiating Reconstituted Influenza Virosomes as a Non-Live Prototype Vaccine Against Hepatitis C" International Immunology Online (intimm.oupjournals.org) (06/02) Vol. 14, No. 6, P. 615; Hunziker, Isabelle P.; Grabscheid, Benno; Zurbriggen, Rinaldo
In vivo exogenous antigens typically cannot induce cytotoxic T lymphocytes (CTLs), a key player in antiviral defense. A recent study sought to see whether HLA-A*0201-restricted hepatitis C virus (HCV) peptides could be delivered via a non-live prototype vaccine based on immunopotentiating reconstituted influenza virosomes. The pathway was successful, as CTLs were primed and the target cells infected with recombinant vaccinia virus encoding the HCV core protein were specifically lysed. The peptide is protected from numerous degrading viruses when the virosomes are delivered in vitro.
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.